BioXcel Therapeutics, Inc. — Director's Dealing 2026

Jan 13, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2026-01-09

Reporting Person: MUELLER PETER (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-09	Stock Option (Right to Buy)	$2.01	A	17000	Acquired	2036-01-09	Common Stock (17000)	Direct

Footnotes

F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.